Davenport & Co
MIRM icon

Davenport & Co’s Mirum Pharmaceuticals MIRM Stock Holding History

Davenport & Co’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$244K Buy
2,855
+50
+2% +$5.22K ﹤0.01% 1271
2026
Q2 		$328K Buy
2,805
+155
+6% +$15.6K ﹤0.01% 1163
2026
Q1 		$245K Buy
+2,650
New +$249K ﹤0.01% 1207

Other funds holding MIRM

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return

Davenport & Co's MIRM Position: Q3 2026 in Review

Davenport & Co increased its Mirum Pharmaceuticals (MIRM) stake by 1.8% in Q3 2026, buying an estimated $5.22K and bringing the position to 2,855 shares worth $244K. The position accounts for ﹤0.01% of the portfolio, ranked #1271.

Davenport & Co first reported a position in MIRM in Q1 2026 and has held it in 3 quarters since. The position peaked at $328K in Q2 2026. 231 funds tracked by Wall St. Rank hold MIRM as of Q3 2026.

  • Davenport & Co held 2,855 shares of Mirum Pharmaceuticals worth $244K as of Q3 2026.
  • Davenport & Co bought 50 Mirum Pharmaceuticals shares in Q3 2026, an estimated $5.22K.
  • Mirum Pharmaceuticals made up ﹤0.01% of Davenport & Co's portfolio in Q3 2026, its #1271 holding.
  • Davenport & Co first reported a position in Mirum Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • Davenport & Co's Mirum Pharmaceuticals position peaked at $328K in Q2 2026.
  • 231 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q3 2026.

Based on Davenport & Co's 13F filing for Q3 2026, filed 14 Oct 2026.